Actively Recruiting
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Led by University Hospital, Lille · Updated on 2026-04-22
80
Participants Needed
11
Research Sites
376 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
S
Société de Dermatologie Française
Collaborating Sponsor
AI-Summary
What this Trial Is About
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.
CONDITIONS
Official Title
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults diagnosed with DRESS based on rash occurring 24 hours to 2 months after medication, fever over 38°C, organ dysfunction, and hematological anomalies including eosinophilia ≥ 500/mm3 or RegiSCAR Score ≥ 4
- Adults with drug-induced rash without severe symptoms lasting over 21 days or causing organ damage
- Adults with drug-induced rash without eosinophilia (blood eosinophils < 500/mm3)
- Adults with drug-induced rash with eosinophilia (blood eosinophils ≥ 500/mm3)
You will not qualify if you...
- Other causes of eosinophilia such as cancer or blood diseases before suspected drug use
- Use of oral or local corticosteroids, anti-leukotriene therapy in the month before the study
- Use of anti-IgE, anti-IL-5, or anti-IL4/IL13 therapies in the 6 months before the study
- Pregnant or breastfeeding women
- Contraindication to the volume of blood drawn for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
CH d'Arras
Arras, France
Actively Recruiting
2
CH de Boulogne
Boulogne-sur-Mer, France
Actively Recruiting
3
Assistance Publique - Hôpitaux de Paris - HENRI MONDOR
Créteil, France
Actively Recruiting
4
CH de Douai
Douai, France
Actively Recruiting
5
CH de Dunkerque
Dunkirk, France
Actively Recruiting
6
CH LENS
Lens, France
Actively Recruiting
7
Hop Claude Huriez Chr Lille
Lille, France, 59000
Actively Recruiting
8
Groupe Hospitalier de l'Institut Catholique de Lille
Lille, France
Actively Recruiting
9
CH de Roubaix
Roubaix, France
Actively Recruiting
10
Hôpital FOCH
Suresnes, France
Actively Recruiting
11
CH de Valenciennes
Valenciennes, France
Actively Recruiting
Research Team
D
Delphine Staumont-Salle, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here